Jump to section
To help improve patient outcomes and cure cancer faster by learning from the experiences of every cancer patient.
Flatiron Health has developed a range of sophisticated analytics, which is utilised in the treatment of cancer. Flatiron was formed in 2012, and was purchased by global pharmaceutical giant Roche for $1.9 billion in 2018.
Data is central to the company’s operation, with Flatiron capturing oncology information from various source systems, with an analytics engine deriving operative conclusions from this data. This assists healthcare organisations in the understanding and treatment of various cancers.
While Flatiron is no longer publicly listed, Roche’s share price has increased steadily since its acquisition of the cancer analysis firm. While there is extensive competition in oncology, with rivals in this space - such as Paige, Live Better With, and Foundation Medicine - Flatiron has continued to grow, making international partnerships and boosting its executive leadership team.
Kirsty
Company Specialist at Welcome to the Jungle
Jan 2016
$175m
SERIES C
May 2014
$130m
SERIES B
This company has top investors
Carolyn Starrett
(CEO, not founder)After working as VP of Partnerships and Business Operations at Intent Media, they joined Flatiron Health in 2016. First serving as VP of Customer Experience and Operations, they later became SVP & GM of Flatiron HC and ultimately became CEO in 2021.
Finance, Legal & Compliance
Sales & Account Management